Timing of SARS-CoV-2 vaccination during the third trimester of pregnancy and transplacental antibody transfer: a prospective cohort study
| Autor: | Gila Zarbiv, Dana G. Wolf, Olesya Vorontsov, Roy Zigron, Amihai Rottenstreich, Esther Oiknine-Djian, Shay Porat, Geffen Kleinstern |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Adult
Microbiology (medical) medicine.medical_specialty COVID-19 Vaccines Placenta Pregnancy Trimester Third medicine.medical_treatment Passive immunity Antibodies Viral Cohort Studies Cordblood Pregnancy Interquartile range medicine Humans Prospective Studies Pregnancy Complications Infectious Prospective cohort study BNT162 Vaccine Coronavirus disease 2019 SARS-CoV-2 Obstetrics business.industry Vaccination Infant Newborn COVID-19 Infant Transplacental Gestational age General Medicine medicine.disease Serology Infectious Diseases Immunoglobulin G Spike Glycoprotein Coronavirus Gestation Female Original Article business severe acute respiratory syndrome coronavirus 2 |
| Zdroj: | Clinical Microbiology and Infection |
| ISSN: | 1198-743X |
| DOI: | 10.1016/j.cmi.2021.10.003 |
| Popis: | Objective We aimed to assess the impact of early versus late third-trimester maternal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination on transplacental transfer and neonatal levels of SARS-CoV-2 antibodies. Methods Maternal and cord blood sera were collected following term delivery after antenatal SARS-CoV-2 BNT162b2 mRNA vaccination, with the first vaccine dose administered between 27 and 36 weeks of gestation. SARS-CoV-2 spike protein (S) and receptor-binding domain (RBD) -specific, IgG levels and neutralizing potency were evaluated in maternal and cord blood samples. Results The study cohort consisted of 171 parturients—median age 31 years (interquartile range (IQR) 27–35 years); median gestational age 39+5 weeks (IQR 38+5–40+4 weeks)–83 (48.5%) were immunized in early thrird-trimester (first dose at 27–31 weeks) and 88 (51.5%) were immunized in late third trimester (first dose at 32–36 weeks). All mother–infant paired sera were positive for anti S- and anti-RBD-specific IgG. Anti-RBD-specific IgG concentrations in neonatal sera were higher following early versus late third-trimester vaccination (median 9620 AU/mL (IQR 5131–15332 AU/mL) versus 6697 AU/mL (IQR 3157–14731 AU/mL), p 0.02), and were positively correlated with increasing time since vaccination (r = 0.26; p 0.001). Median antibody placental transfer ratios were increased following early versus late third-trimester immunization (anti-S ratio: 1.3 (IQR 1.1–1.6) versus 0.9 (IQR 0.6–1.1); anti-RBD-specific ratio: 2.3 (IQR 1.7–3.0) versus 0.7 (IQR 0.5–1.2), p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|